Announcement by Sumitomo Pharma America, Inc. (SMPA) Regarding the U.S. Orphan Drug Designation for an Allogeneic iPS cell-derived Retinal Sheet (3-dimensional retina) as a Treatment for Retinitis Pigmentosa

2026.03.24

Research and Development

Announcement on the Approval for Manufacturing and Marketing Authorization of the Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cell Product “AMCHEPRY®” in Japan

2026.03.06

Research and Development

Announcement on the Submission of the Application of Manufacturing and Marketing Authorization for Allogeneic iPS Cell-Derived dopaminergic neural progenitor cells in Japan

2025.12.24

Research and Development

RACTHERA Inc. Corporate Website Launch Announcement

2025.12.24

Company